Immune-Based Treatment Shows Promise against Metastatic Cervical Cancer
April 16, 2015 by NCI Staff
Two patients with metastatic cervical cancer had a complete disappearance of their tumors after receiving treatment with a form of immunotherapy called adoptive cell transfer (ACT). A third patient experienced a reduction in tumor size for a short time following the treatment.
The treatment tested in the trial consisted of an infusion of immune cells—know as tumor-infiltrating lymphocytes (TILs)—that were collected from each patient’s own tumor and expanded in the laboratory. ACT has had success in small clinical trials of patients with melanoma and some blood cancers conducted by researchers at NCI and several other institutions.
But this is the first time ACT has been tested in patients with cervical cancer, explained the study’s lead author, Christian Hinrichs, M.D., of CCR’s Surgery Branch.
Nearly all cervical cancers are caused by persistent infections with certain types of the human papillomavirus (HPV). HPV-infected cells produce specific proteins, or antigens—known as E6 and E7—that can be recognized by T cells, which are immune cells that play a critical role in the body’s response to infectious agents and infected cells. All of the patients in the trial had tumors that express the E6 and E7 proteins.
The researchers selected for expansion those T cells that would have the greatest likelihood of attacking cancer cells. They did this chiefly by identifying those that were most reactive for the E6 and E7 proteins, although other characteristics were also considered. Patients received chemotherapy before infusion of the expanded T cells and regular infusions with IL-2 for up to three days afterward, both of which have been shown to enhance T cells’ ability to eradicate cancer cells.
The findings published in JCO cover the nine patients in the trial with cervical cancer. The trial also includes patients with other HPV-related cancers, including oropharyngeal and anal cancer.
The two complete responses were ongoing 22 and 15 months after treatment, respectively. One partial response lasted for 3 months. The three patients whose tumors responded to treatment had T cells that were reactive to the HPV proteins. They also had reactive T cells in samples of blood collected one month after treatment. There were no apparent side effects related to the cell infusion, the researchers reported, although most patients experienced side effects from the pre-infusion chemotherapy and post-infusion IL-2 treatments.
“There’s been a lot of hope that’s come from seeing the complete, long-lasting tumor responses in cellular therapy for melanoma and B-cell cancers,” Dr. Hinrichs said. “For the first time, we’re seeing that sort of response in an epithelial cancer.”
Despite coming from a trial with such a small number of patients, “these results are impressive and suggest that this highly personalized therapeutic modality warrants further investigation,” wrote Kunle Odunsi, M.D., Ph.D., of the Roswell Park Cancer Institute, and his colleagues in an accompanying editorial in JCO.
Based on these early results, the trial protocol has been amended so that only patients whose TILs are reactive for the E6 and E7 proteins will receive the treatment. “This way we can only treat the patients with the highest likelihood of responding to the treatment,” Dr. Hinrichs said.
Another trial testing a different form of ACT in patients with HPV-related cancers has been opened at NCI, Dr. Hinrichs added. That trial involves genetically engineering T cells collected from patients’ blood (rather than their tumors) to express a receptor that’s specific for the E6 and E7 proteins.